Kalaitzidis Rigas G, Karasavvidou Despina P, Tatsioni Athina, Pappas Kosmas, Katatsis Giorgos, Liontos Angelos, Elisaf Moses S
Rigas G Kalaitzidis, Despina P Karasavvidou, Kosmas Pappas, Giorgos Katatsis, Angelos Liontos, Moses S Elisaf, Outpatient Renal and Hypertension Clinic, University Hospital of Ioannina, 45110 Ioannina, Greece.
World J Nephrol. 2015 Jul 6;4(3):406-14. doi: 10.5527/wjn.v4.i3.406.
To access the association between albuminuria levels and arterial stiffness in non-diabetic patients with hypertension and chronic kidney disease (CKD) stages 1-2, treated with renin angiotensin blockade agents plus other hypertensive drugs when needed.
One hundred fifteen patients [median age 52 years (68% males)] were consequently enrolled in the study. For each patient, we recorded gender, age, body mass index (BMI), peripheral systolic blood pressure (pSBP), peripheral diastolic blood pressure, peripheral pulse pressure, central systolic blood pressure (cSBP), central diastolic blood pressure (cDBP), central pulse pressure (cPP), hematocrit, hemoglobin, hsCRP, total cholesterol triglycerides, high-density lipoprotein-C, low-density lipoprotein-C, calcium, phosphorus, parathormone, and albumin, as well as 24 h urine albumin excretion. According to 24-h urine albumin collection, patients were then classified as those with moderately increased albuminuria (formerly called macroalbuminuria) (≤ 300 mg/d) and those with severely increased albuminuria (formerly called macroaluminuria (> 300 mg/d). We considered aortic stiffness (AS) indices [carotid femoral pulse wave velocity (PWVc-f) and augmentation index (AIx)] as primary outcomes of the study. We explored potential correlations between severely increased albuminuria and AS indices using a multiple linear regression model.
Fifty-eight patients were included in the moderately increased albuminuria group and 57 in the severely increased albuminuria. Blood pressure measurements of the study population were 138 ± 14/82 ± 1.3 mmHg (systolic/diastolic). There were no significant differences in age, sex, and BP measurements between the two groups. Patients with severely increased albuminuria had higher PWV and AIx than patients with moderately increased albuminuria (P < 0.02, P < 0.004, respectively). In addition these patients exhibited higher BMI (P < 0.03), hsCRP (P < 0.001), and fibrinogen levels (P < 0.02) compared to patients with moderately increased albuminuria. In multivariate linear regression analysis, severely increased albuminuria (β = 1.038, P < 0.010) pSBP (β = 0.028, P < 0.034) and Ht (β = 0.171, P = 0.001) remained independent determinants of the increased PWVc-f. Similarly, severely increased albuminuria (β = 4.385, P < 0.012), cSBP (β = 0.242, P < 0.001), cPP (β = 0.147, P < 0.01) and Ht levels (β = 0.591, P < 0.013) remained independent determinants of increased AIx.
These findings demonstrate an independent association between AS indices and severely increased albuminuria in non-diabetic, hypertensive patients with CKD stages 1-2 treated with renin angiotensin aldosterone system blockers.
评估1-2期慢性肾脏病(CKD)且患有高血压的非糖尿病患者,在使用肾素血管紧张素阻断剂并按需加用其他降压药物治疗时,蛋白尿水平与动脉僵硬度之间的关联。
共有115例患者[中位年龄52岁(68%为男性)]纳入本研究。我们记录了每位患者的性别、年龄、体重指数(BMI)、外周收缩压(pSBP)、外周舒张压、外周脉压、中心收缩压(cSBP)、中心舒张压(cDBP)、中心脉压(cPP)、血细胞比容、血红蛋白、超敏C反应蛋白(hsCRP)、总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、钙、磷、甲状旁腺激素和白蛋白,以及24小时尿白蛋白排泄量。根据24小时尿白蛋白收集情况,患者随后被分为中度蛋白尿增加(原称大量蛋白尿)(≤300mg/d)和重度蛋白尿增加(原称大量蛋白尿>300mg/d)两组。我们将主动脉僵硬度(AS)指标[颈股脉搏波速度(PWVc-f)和增强指数(AIx)]视为研究的主要结局。我们使用多元线性回归模型探讨重度蛋白尿增加与AS指标之间的潜在相关性。
中度蛋白尿增加组纳入58例患者,重度蛋白尿增加组纳入57例患者。研究人群的血压测量值为138±14/82±1.3mmHg(收缩压/舒张压)。两组在年龄、性别和血压测量方面无显著差异。重度蛋白尿增加的患者比中度蛋白尿增加的患者具有更高的PWV和AIx(分别为P<0.02,P<0.004)。此外,与中度蛋白尿增加的患者相比,这些患者的BMI(P<(此处似乎有误,原文应为<0.03))、hsCRP(P<0.001)和纤维蛋白原水平(P<0.02)更高。在多变量线性回归分析中,重度蛋白尿增加(β=1.038,P<0.010)、pSBP(β=0.028,P<0.034)和血细胞比容(β=0.171,P=0.001)仍然是PWVc-f升高的独立决定因素。同样,重度蛋白尿增加(β=4.385,P<0.012)、cSBP(β=0.242,P<0.001)、cPP(β=0.147,P<0.01)和血细胞比容水平(β=0.591,P<0.013)仍然是AIx升高的独立决定因素。
这些发现表明,在使用肾素血管紧张素醛固酮系统阻滞剂治疗的1-2期CKD非糖尿病高血压患者中,AS指标与重度蛋白尿增加之间存在独立关联。